Skip Chemo Safely: New Genomic Test for Breast Cancer

Indeed, recent trial data show that genomic testing breast cancer protocols can help patients safely avoid toxic treatments. Consequently, doctors can now personalize care and minimize chemotherapy use. For instance, a major study presented at the ASCO meeting highlights how molecular profiling identifies candidates for de-escalated therapy.

Advancing Care with Genomic Testing Breast Cancer Protocols

Specifically, researchers analyzed Veracyte’s Prosigna test in a large randomized trial. This trial evaluated over 4,400 patients with early-stage, aggressive breast cancer. Remarkably, more than two-thirds of the patients safely skipped chemotherapy because the test guided their care. Additionally, the Prosigna group achieved a five-year cancer-free survival rate of 93.7%. This rate matched the standard care survival rate of 94.9%. To explain, the genomic test analyzes the activity of 50 specific genes in tumor tissue. Therefore, it generates a precise Risk of Recurrence score to guide clinical decisions. Clearly, this reduces the severe physical and emotional toll of chemotherapy. For example, chemotherapy often causes infertility, cognitive impairment, and nerve damage in younger survivors who may benefit from specialized clinical oncology training.

Predicting Treatment Benefits in Prostate Cancer

Separately, researchers investigated Veracyte’s Decipher test for patients with metastatic, hormone-sensitive prostate cancer. The test successfully predicted which patients would benefit from adding the chemotherapy drug docetaxel to standard care. Meanwhile, another clinical trial compared the cognitive impacts of two common prostate cancer therapies. Specifically, the ARACOG study compared darolutamide (Nubeqa) with enzalutamide (Xtandi). Patients receiving Nubeqa experienced significantly smaller declines in thinking and memory skills. For instance, Nubeqa patients had a median cognitive decrease of 15.8%, whereas Xtandi patients showed a 36.1% drop. Consequently, these findings will likely influence treatment choices when both options exist for practitioners focused on advanced cancer management.

Managing Thrombocytopenia with Oral Therapy

Furthermore, patients with gastrointestinal cancers received help from an oral medication to maintain their planned chemotherapy schedules. Low blood platelet counts, known as thrombocytopenia, often force oncologists to delay chemotherapy doses. To address this, researchers evaluated Doptelet (avatrombopag), an oral drug currently approved for liver disease. Amazingly, the drug proved so effective that investigators stopped the trial early. Indeed, nearly 66% of patients on Doptelet recovered and maintained their platelet counts. Conversely, only 17% of patients receiving a placebo achieved the same recovery. Ultimately, this oral option offers a highly appealing alternative to weekly injections like Nplate (romiplostim), representing a significant update for those keeping up with the latest advancements in hematology.

Frequently Asked Questions

Q1: What is the primary benefit of the Prosigna genomic test?

The Prosigna test analyzes tumor tissue genes to assess recurrence risk, helping early-stage breast cancer patients safely skip unnecessary chemotherapy.

Q2: How does darolutamide compare to enzalutamide regarding cognitive side effects?

A clinical study showed that darolutamide caused significantly less cognitive decline (15.8% median decrease) compared to enzalutamide (36.1% median decrease) over 24 weeks.

Q3: How does Doptelet help gastrointestinal cancer patients?

Doptelet is an oral medication that helps recover and maintain blood platelet counts, preventing chemotherapy delays due to thrombocytopenia.

References

1. Veracyte genomic test identifies breast cancer patients who can skip chemo – ETHealthworld
2. OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer – Veracyte, Inc.
3. Less Cognitive Decline With Darolutamide Treatment Than Enzalutamide in People With Advanced Prostate Cancer – ASCO
4. Oral Medication Proves Effective for Low Platelets Due to Chemotherapy – InventUM

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.